These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 17159544)
1. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544 [TBL] [Abstract][Full Text] [Related]
2. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Jiao LR; Szyszko T; Al-Nahhas A; Tait P; Canelo R; Stamp G; Wasan H; Lowdell C; Philips R; Thillainayagam A; Bansi D; Rubello D; Limongelli P; Woo K; Habib NA Eur J Surg Oncol; 2007 Jun; 33(5):597-602. PubMed ID: 17433608 [TBL] [Abstract][Full Text] [Related]
3. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530 [TBL] [Abstract][Full Text] [Related]
4. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860 [TBL] [Abstract][Full Text] [Related]
5. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094 [TBL] [Abstract][Full Text] [Related]
6. F-18 FDG PET/CT in the management of thyroid cancer. Iagaru A; Kalinyak JE; McDougall IR Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020 [TBL] [Abstract][Full Text] [Related]
7. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. Mancini R; Carpanese L; Sciuto R; Pizzi G; Golfieri R; Giampalma L; Cappelli A; Galaverni MC; Blotta A; Fiore F; Izzo F; Lastoria S; Mastro A; Di Marzo M; Cagol PP; Gasparini D; Geatti O; Bacchetti S; Pasqual E; Zeuli M; Paoletti G; Garufi C; Cosimelli M; In Vivo; 2006; 20(6A):711-4. PubMed ID: 17203751 [TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443 [TBL] [Abstract][Full Text] [Related]
9. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. Du Y; Cullum I; Illidge TM; Ell PJ J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153 [TBL] [Abstract][Full Text] [Related]
10. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925 [TBL] [Abstract][Full Text] [Related]
11. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365 [TBL] [Abstract][Full Text] [Related]
12. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases. Huguet EL; Old S; Praseedom RK; Balan KK; Gibbs P; Jamieson NV Hepatogastroenterology; 2007 Sep; 54(78):1667-71. PubMed ID: 18019690 [TBL] [Abstract][Full Text] [Related]
13. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757 [TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575 [TBL] [Abstract][Full Text] [Related]
15. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387 [TBL] [Abstract][Full Text] [Related]
16. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin. Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438 [TBL] [Abstract][Full Text] [Related]
17. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421 [TBL] [Abstract][Full Text] [Related]
18. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors]. Wu ZJ; Zhang YX; Wei H; Jia Q Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544 [TBL] [Abstract][Full Text] [Related]
19. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700 [TBL] [Abstract][Full Text] [Related]
20. State of the art: radiolabeled microspheres treatment for liver malignancies. Deleporte A; Flamen P; Hendlisz A Expert Opin Pharmacother; 2010 Mar; 11(4):579-86. PubMed ID: 20163269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]